Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Follicular 6Prostatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Urinary Bladder Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Chordoma 1Carcinoma, Transitional Cell 1

Interventions

Temozolomide 2tazemetostat 1talazoparib 1irinotecan sucrosofate 1etoposide phosphate 1dinutuximab 1atezolizumab 1abemaciclib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Phantoms, Imaging 1Nivolumab 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Eflornithine 1Dasatinib 1Carboplatin 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdoid Tumor × tazemetostat × Clear all
NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
49 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡